BNT162b2新冠疫苗在以色列六家医院医护人员中预防SARS-CoV-2感染的早期有效性(CoVEHPI)
本研究在以色列6家医院医护人员中开展前瞻性研究,评估BNT162b2 mRNA新冠疫苗预防SARS-CoV-2感染的有效性。1250名基线未感染参与者中,998人(79.8%)接种第一剂。调整后两剂疫苗对PCR确诊感染的VE为94.5%(95%CI:82.6%-98.2%),对PCR/血清学联合终点的VE为94.5%(95%CI:63.0%-99.0%)。
要点
- 调整后两剂BNT162b2对PCR确诊SARS-CoV-2感染的VE为94.5%(95%CI:82.6%-98.2%)。
- 调整后两剂对PCR/血清学联合终点的VE为94.5%(95%CI:63.0%-99.0%)。
- 接种组4例PCR阳性,未接种组9例PCR阳性;测序样本均为alpha变异株。
核心结论
- 在alpha变异株流行为主期间,两剂辉瑞BNT162b2 mRNA疫苗对近期接种的医护人员SARS-CoV-2感染显示很高的疫苗有效性。
研究设计与样本
- 前瞻性研究,在以色列6家医院医护人员中开展,估计BNT162b2 mRNA新冠疫苗预防SARS-CoV-2感染的有效性。
- 2020年12月27日至2021年2月15日共纳入1567名医护人员,其中1250名基线未感染者纳入主要分析;998人(79.8%)在入组前或入组时接种第一剂,均接种辉瑞BNT162b2 mRNA疫苗。
- 参与者每周填写症状问卷、提供鼻拭子标本,并在入组时、30天和90天采集三份血清学样本。
- 采用Cox比例风险模型估计对PCR确诊SARS-CoV-2感染的VE,采用Fisher精确检验估计对PCR/血清学联合终点的VE。
主要发现
- 接种组发生4例PCR阳性事件,未接种组发生9例PCR阳性事件。
- 调整后两剂疫苗对任何PCR确诊感染的VE为94.5%(95%CI:82.6%-98.2%)。
- 调整后两剂疫苗对60天随访期内PCR与血清阳转联合终点的VE为94.5%(95%CI:63.0%-99.0%)。
- 对5份PCR阳性样本进行测序,均为alpha变异株。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Methodologically rigorous studies on Covid-19 vaccine effectiveness (VE) in preventing SARS-CoV-2 infection are critically needed to inform national and global policy on Covid-19 vaccine use. In Israel, healthcare personnel (HCP) were initially prioritized for Covid-19 vaccination, creating an ideal setting to evaluate early real-world VE in a closely monitored population. METHODS: We conducted a prospective study among HCP in 6 hospitals to estimate the effectiveness of the BNT162b2 mRNA Covid-19 vaccine in preventing SARS-CoV-2 infection. Participants filled out weekly symptom questionnaires, provided weekly nasal specimens, and three serology samples - at enrollment, 30 days and 90 days. We estimated VE against PCR-confirmed SARS-CoV-2 infection using the Cox Proportional Hazards model and against a combined PCR/serology endpoint using Fisher's exact test. RESULTS: Of the 1567 HCP enrolled between December 27, 2020 and February 15, 2021, 1250 previously uninfected participants were included in the primary analysis; 998 (79.8%) were vaccinated with their first dose prior to or at enrollment, all with Pfizer BNT162b2 mRNA vaccine. There were four PCR-positive events among vaccinated participants, and nine among unvaccinated participants. Adjusted two-dose VE against any PCR-confirmed infection was 94.5% (95% CI: 82.6%-98.2%); adjusted two-dose VE against a combined endpoint of PCR and seroconversion for a 60-day follow-up period was 94.5% (95% CI: 63.0%-99.0%). Five PCR-positive samples from study participants were sequenced; all were alpha variant. CONCLUSIONS: Our prospective VE study of HCP in Israel with rigorous weekly surveillance found very high VE for two doses of Pfizer BNT162b2 mRNA vaccine against SARS-CoV-2 infection in recently vaccinated HCP during a period of predominant alpha variant circulation. FUNDING: Clalit Health Services.
引用
- Katz MA, Harlev EB, Chazan B, et al. Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI). Vaccine. 2021. PMID: 34903372. doi:10.1016/j.vaccine.2021.11.092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。